Baptiste Darryl C, Hartwick Andrew T E, Jollimore Christine A B, Baldridge William H, Chauhan Balwantray C, Tremblay François, Kelly Melanie E M
Laboratory for Retina and Optic Nerve Research, Dalhousie University, Halifax, Nova Scotia, Canada.
Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2666-76.
The efficacy of beta1-adrenoceptor (AR)-selective (betaxolol and metoprolol) and nonselective (timolol) antagonists and the alpha2-AR agonist UK14,304 as retinal neuroprotectants was compared and contrasted in an in vitro glutamate excitotoxicity model. The ability of UK14,304, brimonidine, and betaxolol to alter glutamate-receptor-induced changes in intracellular calcium ([Ca2+]i) was also determined in isolated retinal neurons and retinal ganglion cells (RGCs) in an intact retina preparation.
Neuronal survival was measured in mixed retinal cell cultures treated for 24 hours with media containing 100 microM glutamate, with or without the addition of each of the drugs (1-1000 microM). Effects of glutamate on glia were also investigated in a C6 glioma cell line. Glutamate-induced changes in [Ca2+]i with and without UK14,304, and its analogue brimonidine were assessed by calcium-imaging techniques in retinal neurons in culture. The effect of betaxolol on [Ca2+]i was investigated in RGCs in intact rabbit retina.
In cell cultures, 10-1000 microM glutamate resulted in a dose-dependent loss of neurons, but not of glia. The absence of glutamate toxicity in glia was confirmed in C6 glioma cells. Betaxolol, but not timolol or metoprolol, significantly increased survival (from 52% of control in glutamate-only to 78% with 10 microM betaxolol) after excitotoxic insult. UK14,304 also increased survival (from 62% of control in glutamate only to 109% and 101% of control with 10 and 100 microM UK14,304, respectively). This effect was blocked by the specific alpha2-antagonist, yohimbine. Both UK14,304 and brimonidine (10-100 microM) reduced glutamate-induced [Ca2+]i increases in retinal neurons in culture. The actions of the alpha2-agonists in reducing glutamate-induced [Ca2+]i increases were reduced by yohimbine (1 microM). Betaxolol (100 microM) reduced N-methyl-D-aspartate (NMDA)-induced increases of [Ca2+]i in RGCs in intact retina.
Betaxolol reduced glutamate excitotoxicity in retinal neurons in vitro through a mechanism independent of beta-AR interactions. UK14,304, acting through alpha2-ARs, was also neuroprotective in vitro. The neuroprotective actions of betaxolol and the alpha2-agonists on retinal neurons may be due, at least in part, to a direct reduction of glutamate receptor-mediated increases of [Ca2+]i.
在体外谷氨酸兴奋性毒性模型中比较并对比β1-肾上腺素能受体(AR)选择性拮抗剂(倍他洛尔和美托洛尔)、非选择性拮抗剂(噻吗洛尔)以及α2-AR激动剂UK14,304作为视网膜神经保护剂的疗效。还在完整视网膜制备中的分离视网膜神经元和视网膜神经节细胞(RGC)中测定了UK14,304、溴莫尼定和倍他洛尔改变谷氨酸受体诱导的细胞内钙([Ca2+]i)变化的能力。
在含有100微摩尔谷氨酸的培养基中处理24小时的混合视网膜细胞培养物中测量神经元存活率,添加或不添加每种药物(1 - 1000微摩尔)。还在C6胶质瘤细胞系中研究了谷氨酸对神经胶质细胞的影响。通过钙成像技术评估在有或没有UK14,304及其类似物溴莫尼定的情况下谷氨酸诱导的[Ca2+]i变化,在培养的视网膜神经元中进行。在完整兔视网膜的RGC中研究了倍他洛尔对[Ca2+]i的影响。
在细胞培养物中,10 - 1000微摩尔谷氨酸导致神经元呈剂量依赖性损失,但神经胶质细胞未受影响。在C6胶质瘤细胞中证实了神经胶质细胞不存在谷氨酸毒性。倍他洛尔而非噻吗洛尔或美托洛尔在兴奋性毒性损伤后显著提高了存活率(从仅谷氨酸处理组的对照组的52%提高到10微摩尔倍他洛尔处理组的78%)。UK14,304也提高了存活率(从仅谷氨酸处理组的对照组的62%分别提高到10微摩尔和100微摩尔UK14,304处理组的对照组的109%和101%)。该作用被特异性α2拮抗剂育亨宾阻断。UK14,304和溴莫尼定(10 - 100微摩尔)均降低了培养的视网膜神经元中谷氨酸诱导的[Ca2+]i升高。育亨宾(1微摩尔)降低了α2激动剂在减少谷氨酸诱导的[Ca2+]i升高中的作用。倍他洛尔(100微摩尔)降低了完整视网膜中RGC中N-甲基-D-天冬氨酸(NMDA)诱导的[Ca2+]i升高。
倍他洛尔通过独立于β-AR相互作用的机制在体外降低视网膜神经元中的谷氨酸兴奋性毒性。通过α2-AR起作用的UK14,304在体外也具有神经保护作用。倍他洛尔和α2激动剂对视网膜神经元的神经保护作用可能至少部分归因于直接减少谷氨酸受体介导的[Ca2+]i升高。